section name header

Pronunciation

peer-i-METH-a-meen

Classifications

Therapeutic Classification: antiprotozoals

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed with high concentrations achieved in blood cells, kidneys, lungs, liver, and spleen. Some enters CSF (13–26% of serum levels).

Metabolism/Excretion: Mostly metabolized by the liver. 20–30% excreted unchanged by the kidneys.

Half-life: 4 days ( in patients with HIV).

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown3 hr2 wk

†Suppressive levels.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS (LARGE DOSES).

Derm: abnormal pigmentation, dermatitis.

GI: atrophic glossitis (high doses), anorexia, diarrhea, nausea.

GU: hematuria.

Hemat: megaloblastic anemia (high doses), neutropenia, pancytopenia, thrombocytopenia.

Resp: dry throat, pulmonary eosinophilia.
Misc: fever.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Toxoplasmosis (in Patients without HIV)

Toxoplasmosis (in Patients with HIV)

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Daraprim